ALLO vs LEN · rev $22.0K vs rev $34.19B
Allogene Therapeutics Inc (ALLO) versus LEN (LEN) — a side-by-side from cached financials, not a winner call.
Allogene Therapeutics Inc (ALLO) is a biotechnology company listed on US.
LEN (LEN) common stock.
Latest reported ALLO revenue for 2024-12-31 was $22.0K. Net income was -$257.6M. Revenue was down 76.8% from 2023-12-31 to 2024-12-31. ALLO currently screens at market cap $258.1M.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
ALLO currently screens at market cap $258.1M. LEN currently screens at market cap $0.
Not investment advice. Open the ALLO and LEN stock pages for the full models.
Not investment advice.